Early Progression of Follicular Lymphoma: Biology and Treatment

Jodi J Lipof; Paul M Barr

doi:10.1016/j.hoc.2020.02.009

Early Progression of Follicular Lymphoma: Biology and Treatment

Hematol Oncol Clin North Am. 2020 Aug;34(4):757-769. doi: 10.1016/j.hoc.2020.02.009. Epub 2020 May 5.

Authors

Jodi J Lipof¹, Paul M Barr²

Affiliations

¹ James P. Wilmot Cancer Institute, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA. Electronic address: Jodi_Lipof@urmc.rochester.edu.
² James P. Wilmot Cancer Institute, University of Rochester Medical Center, 601 Elmwood Avenue, Rochester, NY 14642, USA.

PMID: 32586579
DOI: 10.1016/j.hoc.2020.02.009

Abstract

Follicular lymphoma is the most common subtype of indolent non-Hodgkin lymphoma. Although a majority of patients have a favorable prognosis, a subset of patients experiences early treatment failure. Progression of disease within 24 months of initial chemoimmunotherapy is associated with inferior survival. The biology of early progression is the subject of ongoing study and depends on the unique genetic composition of neoplastic cells and their interaction with a complex tumor microenvironment. Clinicogenetic prognostic indices have been developed to identify high-risk patients. Several have been validated but are limited in identifying those at risk for early treatment failure.

Keywords: Early progression; Early relapse; Follicular lymphoma; POD24.

Publication types

Review

MeSH terms

Combined Modality Therapy / methods
Disease Management
Disease Progression
Disease Susceptibility
Humans
Lymphoma, Follicular / diagnosis*
Lymphoma, Follicular / etiology
Lymphoma, Follicular / mortality
Lymphoma, Follicular / therapy
Neoplasm Staging
Prognosis
Recurrence
Treatment Outcome
Tumor Microenvironment